Saeid Babaei

Dr. Babaei’s track record includes over 20 years of academic and corporate experience, during which he has led a number of novel and first-in-class product opportunities to either commercialization or to late-stage development. He brings tremendous business foresight having closed over 25 licensing and strategic alliance transactions, as well as raising over $50 million in equity and debt financing.

Dr. Babaei is currently the Chairman and CEO of Virotek Biosciences, a Canadian biopharmaceutical engaged in the R&D and commercialization of therapeutic and diagnostic solutions for infectious diseases and cancer. ViroNetix as a wholly-owned subsidiary of Virotek is utilizing its mobilization platform for population screening and clinical diagnostics for COVID-19 using governmental approved PCR Testing at a large scale, cost-effectively.

Dr. Babaei holds a Ph.D. and an executive MBA, both from the University of Toronto. He has authored over 50 publications including research papers, conference presentations, and patents. Dr. Babaei is currently a Sessional Lecturer in the MBA Entrepreneurship program at Schulich Business School, York University. He is former Chairman of the Board of Directors of BriaCell Therapeutics and Vaxil Bio Ltd, both clinical-stage immuno-oncology companies listed on TSX-V.